今日上午港股 1. 海天味业 (03288) 首挂涨超3%， 全球酱油龙头上市（全球市占率6.2%），募资100亿港元，中国调味 品市占率4.8%居首。 2. 稳定币概念股普涨， 连连数字涨11%、移卡涨9%、众安在线涨8%，香港《稳定币条例》落地催生行 业利好预期。 3. 黑芝麻智能 (02533) 涨超3%， 拟收购AI芯片企业，扩充汽车/端侧AI产品线，强化全场景解决方案能 力。 点击蓝字，关注我们 8. 龙蟠科技 (02465) 涨超6%， 政策推动固态电池产业化加速（工信部专项研发60亿），公司高镍前驱体 材料适配固态电池技术。 9. 思摩尔国际 (06969) 再跌逾5% ，股东亿纬锂能第三次宣布减持3.5%股份（2.16亿股），持股降至27% 失控股地位。 4. 德林控股 (01709) 涨超3%， 年度溢利预增10%-30%（至1.1-1.3亿港元），子公司突触科技获数千万港 元A轮融资。 5. 晶泰科技 (02228) 涨超4%， AI研发平台产出首款临床候选药PRMT5抑制剂PE-0260，2025年下半年启 动临床。 6. 黄金股集体下跌， 灵宝黄金跌4%、珠峰黄金跌4%，现货金价回调拖 ...

Core Viewpoint - Aptevo Therapeutics Inc's stock is experiencing a significant surge due to promising clinical data from its RAINIER trial for mipletamig, a bispecific antibody for treating acute myeloid leukemia (AML) [1][2][6]. Group 1: Clinical Trial Results - The RAINIER trial showed that the mipletamig triplet therapy achieved remissions in 85% of evaluable frontline AML patients, outperforming competitor studies [3]. - Updated results indicate a strong efficacy advantage and a favorable safety profile, with no cases of cytokine release syndrome (CRS) reported in the trial cohorts [4][5]. - The trial is nearing full enrollment for Cohort 3 at the highest dose level evaluated to date [5]. Group 2: Market Impact and Financials - Following the positive trial results, Aptevo's stock price increased by 137.2%, reaching $6.69 [7]. - The company announced a registered direct offering of $8 million, involving 2.465 million shares and pre-funded warrants at an exercise price of $3.25 per share [6].